Scheduling nabpaclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nabpaclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic ductal adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms SIEGE
- 22 Jun 2017 Status changed from recruiting to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 24 Feb 2016 Planned End Date changed from 1 Feb 2016 to 31 Mar 2016 as reported by United Kingdom Clinical Research Network record.